Multiple signaling molecules are involved in expression of ccl2 and il-1β in response to fsl-1, a toll-like receptor 6 agonist, in macrophages

Korean Journal of Physiology and Pharmacology

Volumn 16, Issue 6, 2012, Pages 447-453

  Won, Keunsoo ^a,b   Kim, Sun Mi ^a   Lee, Sae A ^a   Rhim, Byung Yong ^a   Eo, Seong Kug ^c   Kim, Koanhoi ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c Chonbuk National University   (South Korea)

Author keywords

Chemokine; FSL 1; Monocytes macrophages; TLR6

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AKTI IV; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE C; SP 6001250; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; GENETIC TRANSCRIPTION; MACROPHAGE; MONOCYTIC LEUKEMIA; MONONUCLEAR CELL; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 84876767537     PISSN: 12264512     EISSN: 20933827     Source Type: Journal    
DOI: 10.4196/kjpp.2012.16.6.447     Document Type: Article

References (32)

1. Chiu B. Multiple infections in carotid atherosclerotic plaques. Am Heart J. 1999;138:S534-536.
2. Koren O, Spor A, Felin J, Fåk F, Stombaugh J, Tremaroli V, Behre CJ, Knight R, Fagerberg B, Ley RE, Bäckhed F. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA. 2011;108 Suppl 1:4592-4598.
3. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783-801.
4. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004;101:10679-10684.
5. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest. 2005;115: 3149-3156.
6. Farhat K, Riekenberg S, Heine H, Debarry J, Lang R, Mages J, Buwitt-Beckmann U, Röschmann K, Jung G, Wiesmüller KH, Ulmer AJ. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol. 2008;83:692-701.
7. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11: 155-161.
8. Nakao Y, Funami K, Kikkawa S, Taniguchi M, Nishiguchi M, Fukumori Y, Seya T, Matsumoto M. Surface-expressed TLR6 participates in the recognition of diacylated lipopeptide and peptidoglycan in human cells. J Immunol. 2005;174:1566-1573.
9. Into T, Fujita M, Okusawa T, Hasebe A, Morita M, Shibata K. Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages. Infect Immun. 2002; 70:3586-3591.
10. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, Gullestad L, Damås JK. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol. 2008;28:1909-1919.
11. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med. 2004;36:98-118.
12. Young JL, Libby P, Schönbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost. 2002;88:554-567.
13. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121-1127.
14. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, Rollins BJ, Charo IF. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103:773-778.
15. Schrader JW, Moyer C, Ziltener HJ, Reinisch CL. Release of the cytokines colony-stimulating factor-1, granulocyte-macrophage colony-stimulating factor, and IL-6 by cloned murine vascular smooth muscle cells. J Immunol. 1991;146:3799-3808.
16. Devlin CM, Kuriakose G, Hirsch E, Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci USA. 2002; 99:6280-6285.
17. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:656-660.
18. Chi H, Messas E, Levine RA, Graves DT, Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: Pharmacotherapeutic implications. Circulation. 2004;110:1678-1685.
19. Kang SH, Lee JH, Choi KH, Rhim BY, Kim K. Roles of ERK and NF-kappaB in interleukin-8 expression in response to heat shock protein 22 in vascular smooth muscle cells. Korean J Physiol Pharmacol. 2008;12:171-176.
20. Seneviratne AN, Sivagurunathan B, Monaco C. Toll-like receptors and macrophage activation in atherosclerosis. Clin Chim Acta. 2012;413:3-14.
21. Hazeki K, Nigorikawa K, Hazeki O. Role of phosphoinositide 3-kinase in innate immunity. Biol Pharm Bull. 2007;30:1617-1623.
22. Sandig H, Bulfone-Paus S. TLR signaling in mast cells: Common and unique features. Front Immunol. 2012;3:185.
23. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997;275:665-668.
24. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489-501.
25. El-Kholy W, Macdonald PE, Lin JH, Wang J, Fox JM, Light PE, Wang Q, Tsushima RG, Wheeler MB. The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism. FASEB J. 2003;17:720-722.
26. Kawai T, Akira S. TLR signaling. Cell Death Differ. 2006;13: 816-825.
27. Lee SA, Kim SM, Son YH, Lee CW, Chung SW, Eo SK, Rhim BY, Kim K. Peptidoglycan enhances secretion of monocyte chemoattractants via multiple signaling pathways. Biochem Biophys Res Commun. 2011;408:132-138.
28. Thobe BM, Frink M, Hildebrand F, Schwacha MG, Hubbard WJ, Choudhry MA, Chaudry IH. The role of MAPK in Kupffer cell toll-like receptor (TLR) 2-, TLR4-, and TLR9-mediated signaling following trauma-hemorrhage. J Cell Physiol. 2007; 210:667-675.
29. Asehnoune K, Strassheim D, Mitra S, Yeol Kim J, Abraham E. Involvement of PKCalpha/beta in TLR4 and TLR2 dependent activation of NF-kappaB. Cell Signal. 2005;17:385-394.
30. Cuschieri J, Billigren J, Maier RV. Endotoxin tolerance attenuates LPS-induced TLR4 mobilization to lipid rafts: A condition reversed by PKC activation. J Leukoc Biol. 2006;80: 1289-1297.
31. Fronhofer V, Lennartz MR, Loegering DJ. Role of PKC isoforms in the Fc(gamma)R-mediated inhibition of LPS-stimulated IL-12 secretion by macrophages. J Leukoc Biol. 2006;79:408-415.
32. Sipma H, van der Zee L, van den Akker J, den Hertog A, Nelemans A. The effect of the PKC inhibitor GF109203X on the release of Ca2+ from internal stores and Ca2+ entry in DDT1 MF-2 cells. Br J Pharmacol. 1996;119:730-736.